Immuno-Oncology | Specialty

FL: Updated Data for Immunomodulatory Approaches

January 23rd 2018

Immunomodulatory Therapy for FL: The R-Squared Regimen

January 23rd 2018

Further Considerations for Relapsed/Refractory FL

January 23rd 2018

Treatment Approaches to Relapsed Refractory FL

January 23rd 2018

Optimizing Frontline Therapy and Maintenance in FL

January 23rd 2018

Frontline Treatment Approaches to Follicular Lymphoma

January 23rd 2018

FL: Monitoring to Initiate Therapy and Gauge Response

January 23rd 2018

Risk Stratification and Outcomes in Follicular Lymphoma

January 23rd 2018

Diagnosis and Staging for Follicular Lymphoma

January 23rd 2018

Ipilimumab Approved in Europe for Pediatric Melanoma

January 23rd 2018

Ipilimumab has been approved by the European Commission for the treatment of patients aged 12 and older with unresectable or metastatic melanoma.

Pembrolizumab Promising After Sorafenib in Advanced HCC

January 21st 2018

Treatment with the PD-1 inhibitor pembrolizumab elicited promising progression-free survival and overall survival results in patients with advanced hepatocellular carcinoma who received previous treatment with sorafenib.

Cetuximab Plus Pembrolizumab Well Tolerated in RAS Wild-Type mCRC

January 21st 2018

The combination of cetuximab and pembrolizumab was found to be well tolerated in patients with RAS wild-type metastatic colorectal cancer.

Nivolumab/Ipilimumab Combo Data Encouraging in Advanced GISTs

January 19th 2018

Nivolumab alone and in combination with ipilimumab induced responses in patients with heavily pretreated gastrointestinal stromal tumor.

Dr. Apolo on Managing Toxicities of Checkpoint Inhibitors in Bladder Cancer

January 19th 2018

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing immune-related toxicities from checkpoint inhibitors in patients with bladder cancer.

Published Data Demonstrate Avelumab Activity in Platinum-Refractory Bladder Cancer

January 18th 2018

The PD-L1 inhibitor avelumab induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma.

Dr. Weber on Growing Costs With Triplet and Four-Drug Regimens in Melanoma

January 17th 2018

Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.

Frontline Pembrolizumab Combo Improves Survival in Phase III NSCLC Trial

January 17th 2018

Combining pembrolizumab with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer.

Dr. Plimack on Choosing a Checkpoint Inhibitor in Bladder Cancer

January 16th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses choosing a checkpoint inhibitor in bladder cancer.

Dr. Hammers on the Long-Term Benefits of the CheckMate-214 Study in RCC

January 11th 2018

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the long-term benefits of the CheckMate-214 study in patients with renal cell carcinoma (RCC).

Combinations Continue to Advance RCC Treatment

January 11th 2018

Rana R. McKay, MD, discusses the evolving management of patients with advanced RCC, specifically the future of combinations of with immunotherapy regimens.